Gamco Investors INC. ET AL Has $12.46 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)

Gamco Investors INC. ET AL decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,812 shares of the medical research company’s stock after selling 2,300 shares during the quarter. Gamco Investors INC. ET AL owned approximately 0.13% of Bio-Rad Laboratories worth $12,461,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Boussard & Gavaudan Investment Management LLP purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at about $202,000. Raymond James Trust N.A. purchased a new position in shares of Bio-Rad Laboratories during the second quarter valued at about $212,000. World Asset Management Inc purchased a new position in shares of Bio-Rad Laboratories during the second quarter valued at about $213,000. Regentatlantic Capital LLC purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at about $222,000. Finally, We Are One Seven LLC purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at about $254,000. Hedge funds and other institutional investors own 63.80% of the company’s stock.

NYSE:BIO opened at $276.42 on Friday. Bio-Rad Laboratories, Inc. has a one year low of $231.00 and a one year high of $345.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.16 and a current ratio of 4.49. The stock has a market cap of $8.45 billion, a P/E ratio of 54.25, a price-to-earnings-growth ratio of 3.45 and a beta of 1.07.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.91 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.25). Bio-Rad Laboratories had a return on equity of 3.72% and a net margin of 55.13%. The business had revenue of $545.10 million for the quarter, compared to the consensus estimate of $541.23 million. During the same period in the previous year, the firm earned $0.91 EPS. The company’s revenue was up 2.1% on a year-over-year basis. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 5.47 EPS for the current fiscal year.

BIO has been the topic of several research analyst reports. Barclays initiated coverage on shares of Bio-Rad Laboratories in a research report on Wednesday, September 5th. They set an “equal weight” rating and a $345.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $420.00 price target on shares of Bio-Rad Laboratories in a research report on Monday, September 24th. Goldman Sachs Group initiated coverage on shares of Bio-Rad Laboratories in a research report on Wednesday, October 17th. They set a “buy” rating and a $350.00 price target on the stock. Morgan Stanley initiated coverage on shares of Bio-Rad Laboratories in a research report on Thursday, September 20th. They set an “equal weight” rating and a $335.00 price target on the stock. Finally, Zacks Investment Research cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Bio-Rad Laboratories has a consensus rating of “Buy” and a consensus target price of $338.43.

ILLEGAL ACTIVITY WARNING: “Gamco Investors INC. ET AL Has $12.46 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/gamco-investors-inc-et-al-has-12-46-million-holdings-in-bio-rad-laboratories-inc-bio.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

See Also: Put Option

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply